Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Australia shares fall as tech weighs, Melbourne extends lockdown

09/06/2020 | 09:25pm EST

* Tech rout continues, sub-index hits over 3-week low

* CSL signs agreements for potential COVID-19 vaccines

* Melbourne lockdown extended to late Sept.

Sept 7 (Reuters) - Australian shares fell nearly a percent on Monday, following the previous session's sell-off, after technology shares fell tracking their Wall Street peers on Friday and as Melbourne extended a coronavirus-led lockdown till late September.

The S&P/ASX 200 index fell 0.9% to 5,869.9 points by 0030 GMT on Monday, after it lost 3.1% in the previous session.

Technology stocks, the biggest percentage losers, fell 2.4% to hit their lowest level in more than three weeks.

Their losses follow the tech-heavy Nasdaq index's 1.3% fall on Friday after investors dumped heavyweight technology stocks due to concerns about high valuations.

Compounding worries of an economic recovery, the hot spot state of Victoria on Sunday extended a hard lockdown in Australia's second largest city due to a slower than hoped decline in its infection rate.

Victoria, which now accounts for about 75% of the country's total infections of 26,282, reported 63 new cases and five more deaths on Sunday.

Among tech firms, the biggest decliners were buy now pay later firm Afterpay Ltd down 4% and software firm Xero Ltd lost 2.3%.

Heavyweight financials, down 1%, weighed the most on the index, with top lenders Commonwealth Bank of Australia and Westpac Banking Corp falling 1% and 0.4%, respectively.

In a bright spot, CSL rose 2.8% after the heavyweight biotech firm said it signed an agreement with the Australian government to produce an AstraZeneca and Oxford University COVID-19 vaccine candidate.

CSL also signed an agreement with the government to supply 51 million doses of an alternative potential vaccine it is developing with the University of Queensland.

In New Zealand, the benchmark S&P/NZX 50 index swung between gains and losses. It was down 0.1% by 0049 GMT, with financials dragging the index.

(Reporting by Sameer Manekar in Bengaluru; Editing by Amy Caren Daniel)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
AFTERPAY LIMITED 0.26% 98.56 End-of-day quote.236.61%
ASTRAZENECA PLC -0.67% 7889 Delayed Quote.4.34%
COMMONWEALTH BANK OF AUSTRALIA -0.19% 80.1 End-of-day quote.0.25%
CSL LIMITED -1.16% 296.26 End-of-day quote.7.43%
NASDAQ COMP. -0.05% 12349.366333 Delayed Quote.37.70%
S&P/ASX 200 0.38% 6615.3 Real-time Quote.-1.40%
WESTPAC BANKING CORPORATION 0.10% 20.3 End-of-day quote.-16.22%
XERO LIMITED -1.16% 130.66 End-of-day quote.63.33%
All news about ASTRAZENECA PLC
04:21aMerck KGaA agrees research deal with Artios for 'DNA damage' cancer drugs
04:02aMerck KGaA agrees research deal with Artios for 'DNA damage' cancer drugs
02:57aS.Korea shares close at record high on chip, auto boost
02:17aASTRAZENECA : demonstrates growing leadership in breast cancer at SABCS with dat..
01:09aASTRAZENECA : South Korea reaches deal to buy AstraZeneca's COVID-19 vaccine can..
12/02Pfizer and BioNTech's Covid-19 Vaccine Wins U.K. Authorization -- 7th Update
12/02Pfizer and BioNTech's Covid-19 Vaccine Wins U.K. Authorization -- 6th Update
12/02ASTRAZENECA : U.S. COVID-19 vaccine trial results likely in late-Jan, says healt..
12/02PFIZER, BIONTECH'S COVID-19 VACCINE : What You Need to Know
12/02ASTRAZENECA : As coronavirus soars, U.S. cheers Britain's vaccine approval
More news
Financials (USD)
Sales 2020 26 494 M - -
Net income 2020 2 998 M - -
Net Debt 2020 13 181 M - -
P/E ratio 2020 44,6x
Yield 2020 2,65%
Capitalization 139 B 139 B -
EV / Sales 2020 5,75x
EV / Sales 2021 5,01x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 121,91 $
Last Close Price 106,11 $
Spread / Highest target 46,5%
Spread / Average Target 14,9%
Spread / Lowest Target -37,8%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON1.56%389 985
ROCHE HOLDING AG-3.61%289 019
PFIZER, INC.9.91%226 783
NOVARTIS AG-10.86%207 948
MERCK & CO., INC.-10.03%207 033